Benutzer: Gast  Login
Titel:

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

Dokumenttyp:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Autor(en):
O'Donoghue, Michelle L; Braunwald, Eugene; White, Harvey D; Steen, Dylan P; Lukas, Mary Ann; Tarka, Elizabeth; Steg, P Gabriel; Hochman, Judith S; Bode, Christoph; Maggioni, Aldo P; Im, KyungAh; Shannon, Jennifer B; Davies, Richard Y; Murphy, Sabina A; Crugnale, Sharon E; Wiviott, Stephen D; Bonaca, Marc P; Watson, David F; Weaver, W Douglas; Serruys, Patrick W; Cannon, Christopher P; Steen, Dylan L
Abstract:
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.To evaluate the efficacy and safety of darapladib in patients after an acute coronary syndrome (ACS) event.SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 13,026 participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-el...     »
Zeitschriftentitel:
JAMA
Jahr:
2014
Band / Volume:
312
Heft / Issue:
10
Seitenangaben Beitrag:
1006-15
Sprache:
eng
Volltext / DOI:
doi:10.1001/jama.2014.11061
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/25173516
Print-ISSN:
0098-7484
TUM Einrichtung:
Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (Prof. Schunkert)
 BibTeX